Modified LCH treatment with or without Luvometinib for children
Treatments studied
Part of Blood & lymphatic, Lungs & breathing clinical trials.
This trial tests a new drug called Luvometinib added to a standard chemotherapy regimen for children with Langerhans cell histiocytosis that affects multiple parts of the body. The goal is to see if the combination works better than the standard treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 0–18 years.
- Diagnosed with Langerhans cell histiocytosis (a rare immune cell disorder) confirmed by a biopsy showing specific markers.
- The disease affects more than one body system (like bones, skin, lungs, liver, etc.).
- No previous treatment for this condition.
- Parent or legal guardian must agree to the study and follow all procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted therapy (dabrafenib or trametinib) with chemotherapy (clofarabine) for children with Langerhans cell histiocytosis (LCH) that is high-risk, has come back, or is not responding to other treatments. The goal is to see if this combination can help control the disease.
This trial tests the drug luvometinib for children with a specific type of bone disease called Langerhans cell histiocytosis (LCH). It may help kids who have not been treated before and whose LCH is in certain bones, including the head, face, or spine.
This trial tests a drug called mirdametinib for people with histiocytic disorders, which are rare diseases where certain immune cells grow out of control. It may help shrink tumors and improve symptoms when other treatments haven't worked.
This trial is testing a new targeted pill (luvometinib) alone or with another drug (cytarabine) for people with Langerhans cell histiocytosis that needs whole-body treatment. The goal is to see if the new approach can shrink or control the disease.
This trial tests a combination of two drugs for children and teens with Langerhans cell histiocytosis (LCH) that has not responded to standard treatments or has come back after treatment. The goal is to see if the drugs can shrink lesions and improve symptoms.
This trial tests a study drug, FCN-159, for children with a rare blood/immune disease called Langerhans cell histiocytosis (LCH) that has not responded to standard treatment or has come back. The goal is to see if this drug can shrink the LCH lesions and help the child feel better.
Hear when a new Langerhans Cell Histiocytosis (LCH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.